Predictive Oncology (NASDAQ:POAI – Get Free Report) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Risk and Volatility
Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.
Valuation and Earnings
This table compares Predictive Oncology and Valion Bio, Inc. Common Stock”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Predictive Oncology | $1.66 million | 14.21 | -$12.66 million | ($13.50) | -0.52 |
| Valion Bio, Inc. Common Stock | $780,000.00 | 3.14 | -$8.88 million | ($6.68) | -0.11 |
Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Predictive Oncology and Valion Bio, Inc. Common Stock, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Predictive Oncology | 1 | 0 | 0 | 0 | 1.00 |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
Institutional & Insider Ownership
9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 14.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Predictive Oncology and Valion Bio, Inc. Common Stock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Predictive Oncology | -5,065.23% | -732.73% | -235.55% |
| Valion Bio, Inc. Common Stock | N/A | -138.10% | -63.67% |
Summary
Valion Bio, Inc. Common Stock beats Predictive Oncology on 8 of the 11 factors compared between the two stocks.
About Predictive Oncology
Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
